You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • OP0168 A phase 2a, placebo-controlled, randomized study of ABT-981, an anti-interleukin-1ALPHA and -1BETA dual variable domain immunoglobulin, to treat erosive hand osteoarthritis (EHOA)

Article metrics

Article menu

Download PDFPDF

Oral Presentations
Osteoarthritis: new horizons for treatment
OP0168 A phase 2a, placebo-controlled, randomized study of ABT-981, an anti-interleukin-1ALPHA and -1BETA dual variable domain immunoglobulin, to treat erosive hand osteoarthritis (EHOA)
Free

 

Online download statistics by month:

Online download statistics by month: June 2017 to August 2024

AbstractFullPdf
Jun 20171204
Jul 20174403
Aug 20173200
Sep 201710103
Oct 20176404
Nov 20174401
Dec 20172603
Jan 20186401
Feb 20181206
Mar 20184601
Apr 20182000
May 20183201
Jun 20181201
Jul 20184801
Aug 20181800
Sep 20181002
Oct 20182209
Nov 20181404
Dec 20181201
Jan 2019500
Feb 2019402
Mar 20191102
Apr 2019804
May 2019805
Jun 2019202
Jul 20191203
Aug 2019606
Sep 2019400
Oct 20191606
Nov 2019400
Dec 2019202
Jan 2020401
Feb 2020602
Mar 2020202
Apr 20202002
May 20202402
Jun 20201202
Jul 20201203
Aug 2020402
Sep 20201401
Oct 20201202
Nov 20202205
Dec 20201203
Jan 20211804
Feb 20211601
Mar 20212404
Apr 2021401
May 2021406
Jun 2021001
Jul 2021402
Aug 2021102
Sep 2021001
Oct 202122017
Nov 202121012
Dec 20214208
Jan 20223503
Feb 20222200
Mar 20221904
Apr 20221802
May 202213016
Jun 20222905
Jul 2022600
Aug 20221103
Sep 2022206
Oct 2022603
Nov 2022806
Dec 20221001
Jan 20231204
Feb 20231203
Mar 2023601
Apr 2023001
May 2023003
Jun 2023300
Jul 2023203
Aug 2023200
Sep 2023301
Oct 2023400
Nov 2023401
Dec 2023701
Jan 20241001
Feb 2024600
Mar 2024201
Apr 20241704
May 20243103
Jun 2024500
Aug 2024502
Total13250241